Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.360
Buy
RSI(14)
65.908
Neutral
STOCH(KDJ)(9,3,3)
87.215
Overbought
ATR(14)
1.279
Low Volatility
CCI(14)
124.589
Buy
Williams %R
14.253
Overbought
TRIX(12,20)
0.653
Sell
StochRSI(14)
29.648
Sell
Search
Amylyx Pharmaceuticals Inc
AMLXAdd to Watchlist
20.310USD
-0.440-2.12%
Close 07-31 16:00（ET）Quotes delayed by 15 min
2.26BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-2.12%
5 Days
+10.32%
1 Month
+13.15%
6 Months
+42.13%
Year to Date
+68.13%
1 Year
+163.25%
Key Figures
20.740Open
20.870High
1.83MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.65%Turnover Ratio
20.750Prev. Close
19.295Low
27.84MTurnover
LossP/E Static
8.26P/B
0.00%Div Yield TTM
-58.49%ROA
18.60552wk High
0.68Volume Ratio
-301.74MNet Profit
111.03MShares
-1.4849EPS TTM
-0.15Beta
-63.26%ROE
4.70552wk Low
7.59%Amplitude
63.22%Gross Margin
2.26BMarket Cap
4.06Reward/Risk
3.81%Risk Rate
TradingKey Stock Score of Amylyx Pharmaceuticals Inc
Currency: USD Updated: 2026-07-31Key Insights
Amylyx Pharmaceuticals Inc's fundamentals are relatively weak, and its growth potential is high.Its valuation is considered fairly valued, ranking 45 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 24.89.In the medium term, the stock price is expected to trend up.Despite a good stock market performance over the past month, the company shows weak fundamentals and technicals, which don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Amylyx Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Amylyx Pharmaceuticals Inc Highlights
StrengthsRisks
Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on three investigational therapies across several neurodegenerative and endocrine diseases. Its lead investigational asset is avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist. Avexitide has been evaluated as a treatment for Post-Bariatric Hypoglycemia (PBH) and congenital HI, two indications characterized by hyperinsulinemic hypoglycemia. In addition to avexitide, it is advancing AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol in Wolfram syndrome and progressive supranuclear palsy (PSP), and AMX0114 in amyotrophic lateral sclerosis (ALS). AMX0035 is designed to mitigate neurodegeneration by targeting endoplasmic reticulum stress and mitochondrial dysfunction, two cellular processes central to neuronal cell death and neurodegeneration. AMX0114 is an investigational antisense oligonucleotide.
Undervalued
The company’s latest PE is -13.68, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 115.74M shares, decreasing 6.89% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 59.82K shares of this stock.
Analyst Rating
Based on
11
analysts
Buy
Current Rating
24.889
Target Price
+26.15%
Upside Space
Amylyx Pharmaceuticals Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
11
analysts
Buy
Current Rating
24.889
Target Price
+22.55%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Amylyx Pharmaceuticals Inc
AMLX
11
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
19.966
Buy
MA10
18.948
Buy
MA20
18.391
Buy
MA50
16.418
Buy
MA100
15.862
Buy
MA200
14.835
Buy
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Amylyx Pharmaceuticals Inc Info
Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on three investigational therapies across several neurodegenerative and endocrine diseases. Its lead investigational asset is avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist. Avexitide has been evaluated as a treatment for Post-Bariatric Hypoglycemia (PBH) and congenital HI, two indications characterized by hyperinsulinemic hypoglycemia. In addition to avexitide, it is advancing AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol in Wolfram syndrome and progressive supranuclear palsy (PSP), and AMX0114 in amyotrophic lateral sclerosis (ALS). AMX0035 is designed to mitigate neurodegeneration by targeting endoplasmic reticulum stress and mitochondrial dysfunction, two cellular processes central to neuronal cell death and neurodegeneration. AMX0114 is an investigational antisense oligonucleotide.
Ticker SymbolAMLX
CompanyAmylyx Pharmaceuticals Inc
CEOKlee (Justin)
Websitehttps://www.amylyx.com/
Shareholders
Related Instruments
-0.53%
+0.27%
-2.51%
+0.32%
-1.45%
-0.92%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
-0.90%
+1.30%
-2.15%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of Amylyx Pharmaceuticals Inc (AMLX)?
The current price of Amylyx Pharmaceuticals Inc (AMLX) is 20.31.
What is the symbol of Amylyx Pharmaceuticals Inc?
The ticker symbol of Amylyx Pharmaceuticals Inc is AMLX.
What is the 52-week high of Amylyx Pharmaceuticals Inc?
The 52-week high of Amylyx Pharmaceuticals Inc is 18.61.
What is the 52-week low of Amylyx Pharmaceuticals Inc?
The 52-week low of Amylyx Pharmaceuticals Inc is 4.71.
What is the market capitalization of Amylyx Pharmaceuticals Inc?
The market capitalization of Amylyx Pharmaceuticals Inc is 2.25B.
Is Amylyx Pharmaceuticals Inc (AMLX) currently rated as Buy, Hold, or Sell?
According to analysts, Amylyx Pharmaceuticals Inc (AMLX) has an overall rating of Buy, with a price target of 24.89.
What is the Earnings Per Share (EPS TTM) of Amylyx Pharmaceuticals Inc (AMLX)?
The Earnings Per Share (EPS TTM) of Amylyx Pharmaceuticals Inc (AMLX) is -1.53.